Half-Life (Normalesrd) Hours
55-77/No data
Plasma Protein Binding %
99
Volume Of Distribution L/Kg
No data
Dose For Normal Renal Function
750-1500 mg q12h(susp)-q24h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
No data: 100%[D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
No data: 100%[D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
No data: 100%[D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No data: None
Supplement For Dialysis [Recommendation Level]: Pd
PD: No data: None
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 30-50, [D]
References
Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother. 1996; 40: 556-60. [PMID: 8851570] / Hughes WT, Kennedy W, Shenep JL, Flynn PM, Hetherington SV, Fullen G, et al. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis. 1991; 163: 843-8. [PMID: 2010637]